Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients with myelofibrosis (MF). Zinpentraxin alfa (RO7490677, PRM-151) is a recombinant form of PTX-2 that has shown preclinical antifibrotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Foltz, Lynda, Gupta, Vikas, Hasserjian, Robert, Manshouri, Taghi, Mascarenhas, John, Mesa, Ruben, Pozdnyakova, Olga, Ritchie, Ellen, Veletic, Ivo, Gamel, Katia, Hamidi, Habib, Han, Lyrialle, Higgins, Brian, Trunzer, Kerstin, Uguen, Marianne, Wang, Dao, El-Galaly, Tarec Christoffer, Todorov, Boyan, Gotlib, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Myeloproliferative Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543197/
https://www.ncbi.nlm.nih.gov/pubmed/37165840
http://dx.doi.org/10.3324/haematol.2022.282411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543197/
https://www.ncbi.nlm.nih.gov/pubmed/37165840
http://dx.doi.org/10.3324/haematol.2022.282411

Ejemplares similares